Sydney, May 26, 2006 (ABN Newswire) - Clinical Cell Culture Ltd (ASX: CCE) today announced that the TGA (Therapeutic Goods Administration) has completed its approval process and ReCell(R) has been placed on the Australian Register of Therapeutic Goods (ARTG).
The completion of the approval process follows the earlier recommendation for approval by the TGA's Medical Device Evaluation Committee.
ReCell(R) is a unique medical device that assists plastic, cosmetic, dermatology and burn surgeons in repairing a wide range of skin defects. ReCell(R) is intended for use in patients with injuries of up to 2% of the body surface or 320cm sq.
The completion of the TGA approval process clears the way for first commercial sales of ReCell(R) in Australia in June through our recently appointed dedicated distributor.
ReCell(R) is now approved for sale in 33 countries worldwide, including Germany, Italy, United Kingdom, Argentina and Japan.
About CLINICAL CELL CULTURE LIMITED
Clinical Cell Culture (C3) is a publicly listed biomedical company that develops and distributes a number of tissue-engineered products for the treatment of wounds and other skin defects. Using proprietary tissue-culture/ collection technology, C3 is able to provide innovative treatment solutions derived from the patients own skin, to enhance healing rates, reduce scar formation and reintroduce pigmentation into the skin.
News 
